The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine

Thomas Hope; Soo Huey Yap; Brian Wynhoven; Ned Landau; Jennifer Anne Lewis; Michael Kuiper; Chih-Wei Sheen; Mark Zanin; Nicolas Sluis-Cremer; Richard Harrigan; Gilda Tachedjian

The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine

Thomas Hope (Editor), Soo Huey Yap, Brian Wynhoven, Ned Landau (Editor), Jennifer Anne Lewis, Michael Kuiper, Chih-Wei Sheen, Mark Zanin, Nicolas Sluis-Cremer, Richard Harrigan, Gilda Tachedjian

Microbiology

Research output: Contribution to conference › Abstract

Original language	English
Pages	232 - 232
Number of pages	1
Publication status	Published - 2007
Event	2007 Cold Spring Harbor Laboratory (CSHL) - Cold Spring Harbor NY USA, New York USA Duration: 22 May 2007 → 27 May 2007

Conference

Conference	2007 Cold Spring Harbor Laboratory (CSHL)
City	New York USA
Period	22/05/07 → 27/05/07

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hope, T. (Ed.), Yap, S. H., Wynhoven, B., Landau, N. (Ed.), Lewis, J. A., Kuiper, M., Sheen, C.-W., Zanin, M., Sluis-Cremer, N., Harrigan, R., & Tachedjian, G. (2007). The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine. 232 - 232. Abstract from 2007 Cold Spring Harbor Laboratory (CSHL), New York USA.

@conference{90c59f09683f4366ab96de7de2e4e502,

title = "The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine",

author = "Thomas Hope and Yap, {Soo Huey} and Brian Wynhoven and Ned Landau and Lewis, {Jennifer Anne} and Michael Kuiper and Chih-Wei Sheen and Mark Zanin and Nicolas Sluis-Cremer and Richard Harrigan and Gilda Tachedjian",

year = "2007",

language = "English",

pages = "232 -- 232",

note = "2007 Cold Spring Harbor Laboratory (CSHL) ; Conference date: 22-05-2007 Through 27-05-2007",

}

Hope, T (ed.), Yap, SH, Wynhoven, B, Landau, N (ed.), Lewis, JA, Kuiper, M, Sheen, C-W, Zanin, M, Sluis-Cremer, N, Harrigan, R & Tachedjian, G 2007, 'The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine', 2007 Cold Spring Harbor Laboratory (CSHL), New York USA, 22/05/07 - 27/05/07 pp. 232 - 232.

The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine. / Hope, Thomas (Editor); Yap, Soo Huey; Wynhoven, Brian et al.
2007. 232 - 232 Abstract from 2007 Cold Spring Harbor Laboratory (CSHL), New York USA.

Research output: Contribution to conference › Abstract

TY - CONF

T1 - The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine

AU - Yap, Soo Huey

AU - Wynhoven, Brian

AU - Lewis, Jennifer Anne

AU - Kuiper, Michael

AU - Sheen, Chih-Wei

AU - Zanin, Mark

AU - Sluis-Cremer, Nicolas

AU - Harrigan, Richard

AU - Tachedjian, Gilda

A2 - Hope, Thomas

A2 - Landau, Ned

PY - 2007

Y1 - 2007

UR - http://meetings.cshl.edu/meetings/retro07.shtml

M3 - Abstract

SP - 232

EP - 232

T2 - 2007 Cold Spring Harbor Laboratory (CSHL)

Y2 - 22 May 2007 through 27 May 2007

ER -

The mutation N3481 in the connection domain of the HIV-1 reverse transcriptase is selected in vivo and confers decreased susceptibility to zidovudine and nevirapine

Conference

UN SDGs

Other files and links

Cite this